The FDA has granted a priority review to a new drug application (NDA) for lirafugratinib, a highly selective oral FGFR2 ...

Lirafugratinib, an oral FGFR2 inhibitor, receives FDA Priority Review for advanced cholangiocarcinoma with FGFR2 rearrangements or fusions.

Researchers reported at the 2026 European Lung Cancer Congress that Hernexeos (zongertinib) led to high response rates and ...

Celcuity Inc. (NASDAQ:CELC) Q4 2025 Earnings Call Transcript March 25, 2026 Celcuity Inc. beats earnings expectations.

Beyond both being viruses, HIV-1 and SARS-CoV-2 don't seem to have a lot in common. HIV-1 is a retrovirus that integrates ...

Theodora Hatziioannou used her expertise on HIV-1 to gain insights into SARS-Co-V-2, and vice versa. The potential ...

Celcuity’s latest earnings call struck a notably optimistic tone, as management emphasized powerful Phase III results, a fast-track regulatory path and solid funding that could carry the company into ...

Discusses Proposed Acquisitions of Tubulis, Ouro and Arcellx and Strategic Pipeline Expansion April 7, 2026 4:30 PM ...

UK MHRA grants marketing authorization to Bayer’s sevabertinib to treat adults with HER2-positive lung cancer that has spread or cannot be removed by surgery: United Kingdom Sat ...

The U.S. Food and Drug Administration (“FDA”) accepted Celcuity’s New Drug Application (“NDA”) and granted Priority Review with a Prescription ...

As with any medicine, the MHRA will keep the safety and effectiveness of sevabertinib under close review. The Medicines and Healthcare products ...